SR9011 is a synthetic REV-ERBα/β agonist that exhibits activity in vivo and is considered a lead compound for a new class of cancer drugs associated with the body's circadian clock. It has the potential to be used in various applications due to its effects on different cellular processes.
Used in Pharmaceutical Industry:
SR9011 is used as a nuclear receptor subfamily 1 group D member 1 (NR1D1) receptor agonist for the following applications:
1. To study its effects on microglial immune-metabolism, which could potentially lead to the development of new treatments for neuroinflammatory diseases and other conditions involving the immune system.
2. To study its effects on insulin secretion from human type 2 diabetes islet cells, which may contribute to the development of novel therapies for managing and treating type 2 diabetes.
3. To study its effects on thyroid-stimulating hormone β (TSHβ) gene expression, which could help in understanding the role of SR9011 in thyroid function and potentially lead to new treatments for thyroid-related disorders.
Additionally, SR9011 is used as a lead compound for a new class of cancer drugs associated with the body's circadian clock, which may pave the way for innovative cancer treatment strategies that target the circadian rhythm and its impact on cellular processes.
Used in Pharmaceutical Industry:
SR9011 is used as a nuclear receptor subfamily 1 group D member 1 (NR1D1) receptor agonist for the following applications:
1. To study its effects on microglial immune-metabolism, which could potentially lead to the development of new treatments for neuroinflammatory diseases and other conditions involving the immune system.
2. To study its effects on insulin secretion from human type 2 diabetes islet cells, which may contribute to the development of novel therapies for managing and treating type 2 diabetes.
3. To study its effects on thyroid-stimulating hormone β (TSHβ) gene expression, which could help in understanding the role of SR9011 in thyroid function and potentially lead to new treatments for thyroid-related disorders.
Additionally, SR9011 is used as a lead compound for a new class of cancer drugs associated with the body's circadian clock, which may pave the way for innovative cancer treatment strategies that target the circadian rhythm and its impact on cellular processes.
1379686-29-9 Suppliers
Post Buying RequestRecommended suppliersmore
-
-
Basic information
- Product Name: SR9011
- Synonyms: SR9011;SR9001;3-[[[(4-Chlorophenyl)methyl][(5-nitro-2-thienyl)methyl]amino]methyl]-N-pentyl-1-pyrrolidinecarboxamide
- CAS NO:1379686-29-9
- Molecular Formula: C23H31ClN4O3S
- Molecular Weight: 479.03524
- EINECS: -0
- Product Categories: N/A
- Mol File: 1379686-29-9.mol
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: 642.8±50.0 °C(Predicted)
- Flash Point: N/A
- Appearance: /
- Density: 1.254±0.06 g/cm3(Predicted)
- Refractive Index: N/A
- Storage Temp.: Keep in dark place,Sealed in dry,Store in freezer, under -20°C
- Solubility: Chloroform (Slightly), Methanol (Slightly)
- PKA: 14.71±0.40(Predicted)
- CAS DataBase Reference: SR9011(CAS DataBase Reference)
- NIST Chemistry Reference: SR9011(1379686-29-9)
- EPA Substance Registry System: SR9011(1379686-29-9)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 1379686-29-9(Hazardous Substances Data)
1379686-29-9 Usage
Biochem/physiol Actions
SR9011 is a potent nuclear receptor REV-ERB agonist (EC50 of REV-ERBα- and REV-ERBβ-dependent repressor activity = 790 and 560 nM, respectively, by cell-based reporter assay) that stimulates REV-ERB-dependent target genes suppression both in cultures in vitro and in mice in vivo (100 mg/kg i.p., b.i.d.) without activity toward a panel of 46 other nuclear receptors. SR9011 is shown to modulate circadian behavior by suppressing the transcription factors BMAL1 (brain and muscle ARNT-like protein 1) and CLOCK (circadian locomotor output cycles kaput) as well as induce energy expenditure and weight loss by regulating genes involved in lipid and glucose metabolism in mice in vivo with good bioavailabiilty (plasma conc. = 0.53 and 15.3 μM 2 hr post 10 or 100 mg/kg i.p. dosage; brain conc. = 0.24 μM 2 hr post 10 mg/kg i.p.), while its structure analog GSK4112 shows no plasma exposure.Check Digit Verification of cas no
The CAS Registry Mumber 1379686-29-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,9,6,8 and 6 respectively; the second part has 2 digits, 2 and 9 respectively.Calculate Digit Verification of CAS Registry Number 1379686-29:
(9*1)+(8*3)+(7*7)+(6*9)+(5*6)+(4*8)+(3*6)+(2*2)+(1*9)=229
229 % 10 = 9
So 1379686-29-9 is a valid CAS Registry Number.
1379686-29-9Upstream product
1379686-29-9Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 1379686-29-9
SR9011
